Tutti gli studi
ReclutamentoConferma terapeutica (Fase III)Interventistico

A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria

Phenylketonuria (PKU) is a rare inherited condition where the body cannot properly break down an amino acid called phenylalanine (Phe), which is found in protein. People with PKU must usually stick to a very strict, low-protein diet to protect their brain health. This Phase 3 trial is testing a medicine called PTC923 (sepiapterin). The main goals are to check how safe it is to take over a longer period and to see if it helps the body process Phe more effectively. If successful, it could allow adults with PKU to eat more regular protein. Because this is an 'open-label' study, all participants will receive the active study medicine. Doctors will track side effects, run blood tests, and measure how much dietary protein participants can comfortably tolerate.

A colpo d'occhio

Stato
Reclutamento
Fase
Conferma terapeutica (Fase III)
Sponsor
PTC Therapeutics Inc.
Obiettivo di iscrizione
80
Inizio
02 Feb 2024

Di cosa tratta questo studio?

Phenylketonuria, often shortened to PKU, is a lifelong metabolic condition. People born with PKU lack enough of a working enzyme needed to process phenylalanine (Phe), a natural building block of protein found in foods like meat, fish, dairy, nuts, and even grains. Without strict management, Phe can build up to harmful levels in the blood and brain. Currently, managing PKU often means following a very demanding, low-protein diet and drinking special amino acid supplements every day.

This clinical trial is evaluating an experimental oral medicine called PTC923 (also known as sepiapterin). In the body, sepiapterin turns into a natural substance (BH4) that helps the missing or faulty enzyme work better. The hope is that PTC923 will help people with PKU break down Phe more easily, potentially allowing them to include more everyday protein in their meals.

This is a Phase 3 study, which is the final testing stage before a medicine can be approved for general prescription use. It is also an 'open-label' trial, meaning there is no dummy pill (placebo); everyone who takes part will be given the actual medicine.

Taking part in this research helps scientists understand whether PTC923 is safe over a longer period and whether it genuinely improves daily life and dietary freedom for people living with PKU.

Punti chiave

  • Phase 3 trial assessing the safety and effectiveness of PTC923 (sepiapterin) for PKU.
  • Aims to find out if the treatment allows people to safely eat more natural protein.
  • Open to adults aged 18 and over diagnosed with phenylketonuria.
  • Open-label study, meaning all participants receive the active medicine.
  • Involves regular hospital check-ups, blood monitoring, and dietary assessments.

Chi può essere idoneo?

This study is open to adults aged 18 and older who have been diagnosed with phenylketonuria (PKU). Men and women are both eligible to join.

To take part, you must be able and willing to attend regular clinic appointments, take the study medicine as directed, and follow dietary instructions. This includes keeping track of what you eat during special food assessment periods.

People with certain other unstable health conditions, or those unable to attend regular hospital visits, may not be able to participate. Your PKU specialist or the trial team can confirm your full eligibility based on your medical history.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. I am aged 18 or older.
  2. I have a confirmed medical diagnosis of phenylketonuria (PKU).
  3. I am willing to take an experimental oral medication every day.
  4. I can attend regular clinic visits for blood tests and physical health checks.
  5. I am happy to complete food diaries and quality-of-life questionnaires.
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

Taking part in this study involves taking the study medicine (PTC923) by mouth. You will visit a specialist hospital clinic regularly so doctors can check your general health, record your blood pressure, carry out physical examinations, and take routine blood and urine samples.

A key part of the trial is a dietary assessment. The research team will carefully test how much Phe and natural protein you can safely consume while taking the medicine. You will also be asked to complete short quality-of-life questionnaires to share how you feel day to day and how manageable the treatment is. The trial team will support you throughout the entire study period, which will be explained in detail before you decide to join.

Rischi e benefici potenziali

Potential benefits may include better control of your blood Phe levels and the chance to eat more natural protein under medical supervision, alongside contributing to research that could help many others with PKU. However, there is no guarantee that the medicine will improve your condition. Potential risks include side effects from the study drug, temporary changes in your blood Phe levels during diet adjustments, and mild discomfort from routine blood tests. Your safety is monitored closely at all times. Taking part is completely voluntary, and you can withdraw from the study at any point without affecting your standard NHS care.

Locations (10)

Alcune posizioni dei siti sono approssimative. Stiamo migliorando questo — si prega di verificare con il team di prova prima di viaggiare.
  • —
    Non verificato
    Paesi Bassi
  • —
    Non verificato
    Germania
  • —
    Non verificato
    Spagna
  • —
    Non verificato
    Italia
  • —
    Non verificato
    Danimarca
  • —
    Non verificato
    Portogallo
  • —
    Non verificato
    Polonia
  • —
    Non verificato
    Repubblica Ceca
  • —
    Non verificato
    Francia
  • —
    Non verificato
    Slovenia

Domande comuni

What is the main goal of this trial?

The study aims to check the long-term safety of PTC923 and see if it helps adults with PKU tolerate more protein in their everyday diet.

Will I definitely receive the real medicine?

Yes. This is an open-label trial, so there is no placebo (dummy medicine). All participants receive PTC923.

Do I have to change my diet immediately?

No. Any dietary changes or protein increases will be carefully guided and monitored step-by-step by the trial's metabolic dietitians.

Posso abbandonare lo studio se cambio idea?

Yes. You have the right to withdraw from the trial at any time, for any reason, and your normal medical care will continue as usual.

Does taking part cost anything?

No. The study medication and all trial-related tests are provided free of charge, and travel expenses to clinic visits are usually reimbursed.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenyl…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.